// App-Quantinova.ai

SAT-019 : ACEi/ARBs, β-blockers or Both in incident End-Stage Renal Disease patients without Cardiovascular Disease: A Propensity-Matched longitudinal study in a Nationwide cohort

Researchers

Presenter

  • J.P. Ferreira

Principal Investigators

  • C. Couchoud

  • G. John

  • A. Tiple

  • F. Glowacki

  • G. London

  • R. Agarwal

  • P. Rossignol

Medical Centers

  • Agence de la biomédecine, REIN registry, Saint Denis La Plaine, France

  • Université de Lorraine- INSERM- Centre d'Investigations Cliniques Plurithématique 1433- UMR 1116- CHRU de Nancy, F-CRIN INI-CRCT Cardiovascular and Renal Clinical Trialists, Nancy, France

  • CHRU de Clermont-Ferrand, Service de Néphrologie, Clermont-Ferrand, France

  • Indiana University School of Medicine and Richard L. Roudebush Veterans Administration Medical Center, Department of Medicine, Indianapolis, USA

  • Univ. Lille, EA 4483-IMPECS-IMPact of Environmental ChemicalS on Human Health- Faculté de Médecine/Pôle Recherche, Lille, France

  • Hospital Manhes, Department of Nephrology, Fleury-Mérogis, France

  • London School of Hygiene and Tropical Medicine, Department of medical statistics, London, United Kingdom

Locations

  • France

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

Disease

  • Microvascular complications of diabetes 1

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved